Table 1.
Study demographics.
| GEO entry | N patients (n recurrence) |
Mean age (SD) |
N male (%) |
Median F/U1 (range) |
Median TTR2 (range) |
WHO grade (I II III) [n] |
|---|---|---|---|---|---|---|
| GSE16181 | 252 (92) | 44.1 (12.7) | 53 (21.0) | 10.0 (1.0–15.0) | 3.0 (1.0–14.0) | 140 88 24 |
| GSE43290 | 47 (8) | 61.7 (15.0) | 13 (27.7) | 3.5 (1.4–25.4) | N/A | 33 12 2 |
| GSE16581 | 16 (6) | 58.3 (11.1) | 7 (43.8) | 4.4 (0.3–8.6) | N/A | 8 7 1 |
| GSE74385 | 45 (22) | N/A | N/A | N/A3 | N/A | 17 8 20 |
| GSE136661 | 145 (22) | 58.0 (13.5) | 52 (35.8) | N/A4 | N/A | 116 29 0 |
1Follow-up (years).
2Time to recurrence (years).
3Follow up at least 3 years for non-recurrent tumours, though specific times are not published.
4Follow up reported as 0 to 91 months (up to 7.6 years) with a median of 28 months (2.3 years), though specific times are not available.